Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease

被引：37

作者：

Hoppe, C ^{[1
]}

Vichinsky, E ^{[1
]}

Quirolo, K ^{[1
]}

Van Warmerdam, J ^{[1
]}

Allen, K ^{[1
]}

Styles, L ^{[1
]}

机构：

[1] Childrens Hosp, Dept Hematol Oncol, Oakland, CA 94609 USA

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2000年 / 22卷 / 04期

关键词：

pediatric; sickle cell anemia; therapy;

D O I：

10.1097/00043426-200007000-00009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The efficacy and side effects of hydroxyurea in young children with sickle cell disease are unknown. The authors followed-up eight young children (mean age 3.7 years) during therapy with hydroxyurea for an average of 137 weeks. Total and fetal hemoglobin levels rose with hydroxyurea therapy. Hospital admission rates and total hospital days decreased during hydroxyurea therapy. No unexpected toxicity occurred, and growth and development were unaffected. This pilot study suggests that hydroxyurea is safe and effective in young children with sickle cell disease.

引用

页码：330 / 334

页数：5

共 50 条

[1] Predictors of Hydroxyurea Use in Children with Sickle Cell Disease
Okwor, Chisom Ifeoma
Klaassen, Robert J.
Harrison, Mary-Ann
Tang, Ken
Laforest, Isabelle
Bowerman, Brooke
Simpson, Ewurabena
[J]. BLOOD, 2018, 132
[2] Use of hydroxyurea in prevention of stroke in children with sickle cell disease
Lefevre, Nicolas
Dufour, Dominique
Gulbis, Beatrice
Le, Phu-Quoc
Heijmans, Catherine
Ferster, Alina
[J]. BLOOD, 2008, 111 (02) : 963 - 964
[3] Hydroxyurea for children with sickle cell disease
Heeney, Matthew M.
Ware, Russell E.
[J]. PEDIATRIC CLINICS OF NORTH AMERICA, 2008, 55 (02) : 483 - +
[4] Hydroxyurea for Children with Sickle Cell Disease
Heeney, Matthew M.
Ware, Russell E.
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (01) : 199 - +
[5] The safety and efficacy of hydroxyurea in 2 to 5 year old children with sickle cell disease
Hoppe, C
Van Warmerdam, J
Allen, K
Quirolo, K
Vichinsky, E
Styles, L
[J]. PEDIATRIC RESEARCH, 1999, 45 (04) : 147A - 147A
[6] The Safety and Efficacy of Hydroxyurea in 2 to 5 Year Old Children with Sickle Cell Disease
Carolyn Hoppe
Jane Van Warmerdam
Katie Allen
Keith Quirolo
Elliott Vichinsky
Lori Styles
[J]. Pediatric Research, 1999, 45 (7) : 147 - 147
[7] Use of hydroxyurea in children with sickle cell disease: What comes next?
OheneFrempong, K
SmithWhitley, K
[J]. SEMINARS IN HEMATOLOGY, 1997, 34 (03) : 30 - 41
[8] Is hydroxyurea leukemogenic in children with sickle cell disease?
de Montalembert, M
Davies, SC
[J]. BLOOD, 2001, 98 (09) : 2878 - 2879
[9] Five years of experience with hydroxyurea in children and young adults with sickle cell disease
Ferster, A
Tahriri, P
Vermylen, C
Sturbois, G
Corazza, F
Fondu, P
Devalck, C
Dresse, MF
Feremans, W
Hunninck, K
Toppet, M
Philippet, P
Van Geet, C
Sariban, E
[J]. BLOOD, 2001, 97 (11) : 3628 - 3632
[10] Adherence with Hydroxyurea in Children with Sickle Cell Disease
Thornburg, Courtney D.
Calatroni, Agustin
Herzberg, Brittany
Telen, Marilyn J.
Kemper, Alex
[J]. BLOOD, 2008, 112 (11) : 69 - 69

← 1 2 3 4 5 →